Archive: April, 2012
Pfizer said last July that it might sell its infant nutrition and animal health divisions and the Wall Street Journal reported that Pfizer is close to a $9 billion deal with Nestle on the infant food group.
If it pans out, Nestle will have outbid a group off from Groupe Danone SA, the yogurt makers, and Mead Johnson Nutrition Co.
The link to the Journal story is here.
Johnson & Johnson said first quarter profit rose, but there was slight decrease in total sales and the company is facing increasing costs and delays in fixing the problems at the McNeil Consumer Health Care facility in Fort Washington.
Chief Financial Officer Dominic Caruso had said earlier that well-known consumer brands such as Tylenol and Motrin wouldn't be produced in Fort Washington until 2013, but he said Tuesday that the pace repairs and upgrades was taking longer than hoped.
"We're obviously disappointed that it is taking a little longer to get back into the market," Caruso said on a conference call with stock market analysts. Journalists were allowed to listen but not ask questions. "But all of the indicators of the equity scores that we track with brands continue to show - both Tylenol and Motrin, but especially childrens' products - very highly compared to store brands even though they are not on the shelf, so much so that the scores are in the neighborhood of two to three times the level of trust and confidence in the brands compared to the currently available brands, particularly store brands.
Johnson & Johnson will report first quarter earnings Tuesday morning before the stock market opens in New York and then host a conference call with Wall Street analysts, and it will be interesting to see if company officials are questioned about legal losses in Risperdal litigation.
Dominic Caruso, the J&J chief financial officer, and Louise Mehrotra, the vice president of investor relations, will host the call.
Invited analysts can ask questions. Media can listen but can't ask questions.
GlaxoSmithKline issued its 2011 corporate responsibility report, which explains how the company says it is trying to be a good citizen in the world.
The report has philosophy, charts, graphs and tables that discuss money spent on health-care providers, individuals and groups, carbon footprint and world-wide immunizations for diseases in troubled spots.
The link to get to the report is here.
AstraZeneca and its chief executive officer are reportedly under increasing pressure from investors to boost the fortunes of the pharmaceutical manufacturer that is based in the United Kingdom and has its Americas headquarters in Wilmington. The company also has a plant in Newark, Del.
The Financial Times reported that some of the company's 20 biggest investors are, anonymously, making noise about replacing CEO David Brennan and finding a new strategy. The link to the story is here.
“You don’t need a lawyer or a marketing person. You either need Attila the Hun – a total butcher – to run it down until it can be bought, or a Paul Janssen-like figure: a successful scientist who can really take on the research team,” Bernstein Research analyst Jack Scannell said, according to the FT. A Bernstein Research note sent last month, said, “Our belief is that the status quo is not sustainable.”
Like some folks on Wall Street, some in the pharmaceutical community bemoan the existence of government.....until the government gives them money.
Two examples came Wednesday, when news emerged that Teva Pharmaceuticals might build another facility in New Jersey and and McKesson Inc. was awarded a $31 billion contract to distribute pharmaceuticals to the Veterans Administration.
Inquirer colleague Matt Katz, whose coverage of New Jersey Gov. Christie is first rate, shared a bit of pharma knowledge Wednesday as the governor mentioned that Teva Pharmaceuticals might open a facility in Florham Park.
An Arkansas judge fined Johnson & Johnson $1.2 billion Wednesday because the health-care giant’s Janssen subsidiary marketed the antipsychotic drug Risperdal in misleading ways through that state’s Medicaid system.
The award, if upheld on appeal, could reverberate through the many courts in which J&J is fighting lawsuits about the drug, which was approved only for schizophrenia and bipolar mania but was prescribed for other ailments.
“This is the third one in a row that they’ve lost, and when you see a pattern like this, sometimes discretion is the better part of valor when you’re trying to decide about settling,” said University of Richmond law professor Carl Tobias, who specializes in product liability.
We'll end the week with a couple things worth mentioning.
President Obama signed a bill that got through both houses of Congress - pause to consider that for a moment - which touches investors and the business community: The Jumpstart our Business Startups (JOBS) Act.